1.Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
Hiroyuki SUZUKI ; Tsubasa TSUTSUMI ; Machiko KAWAGUCHI ; Keisuke AMANO ; Takumi KAWAGUCHI
Clinical and Molecular Hepatology 2024;30(4):962-964
2.Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
Hiroyuki SUZUKI ; Tsubasa TSUTSUMI ; Machiko KAWAGUCHI ; Keisuke AMANO ; Takumi KAWAGUCHI
Clinical and Molecular Hepatology 2024;30(4):962-964
3.Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
Tsubasa TSUTSUMI ; Dan NAKANO ; Machiko KAWAGUCHI ; Hirokazu TAKAHASHI ; Takumi KAWAGUCHI
Clinical and Molecular Hepatology 2024;30(2):266-268
5.Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
Hiroyuki SUZUKI ; Tsubasa TSUTSUMI ; Machiko KAWAGUCHI ; Keisuke AMANO ; Takumi KAWAGUCHI
Clinical and Molecular Hepatology 2024;30(4):962-964
6.Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
Hiroyuki SUZUKI ; Tsubasa TSUTSUMI ; Machiko KAWAGUCHI ; Keisuke AMANO ; Takumi KAWAGUCHI
Clinical and Molecular Hepatology 2024;30(4):962-964
7.Osteoclast-Forming Suppressive Compounds from Anoectochilus formosanus
Kikuko MASUDA ; Takumi KAWAGUCHI ; Tomoyuki KOYAMA ; Tomio NISHIMURA ; Hirokazu KAWAGISHI ; Kazunaga YAZAWA
Japanese Journal of Complementary and Alternative Medicine 2010;7(2):121-124
Anoectochilus formosanus, an orchidaceous plant native to Taiwan, is widely used as a folk medicine in Taiwan and other Southeast Asian countries. We attempted to isolate the bioactive principles from A. formosanus and succeeded in purifying the compounds. Two known compounds (N-cis-feruloyl tyramine and N-trans-feruloyl tyramine) were isolated and both significantly inhibited osteoclast formation, which is important in the development of osteoporosis.
10.Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective
Hironori KOGA ; Hideki IWAMOTO ; Hiroyuki SUZUKI ; Shigeo SHIMOSE ; Masahito NAKANO ; Takumi KAWAGUCHI
Clinical and Molecular Hepatology 2023;29(2):242-251
Striking advances in systemic therapy for unresectable advanced hepatocellular carcinoma (HCC) have improved the average prognosis of patients with HCC. As a result, the guidelines for the treatment of HCC have changed significantly. However, various issues have emerged in clinical practice. First, there is no established biomarker that can predict response to systemic therapy. Second, there is no established treatment regimen after primary systemic therapy, including combined immunotherapy. Third, there is no established treatment regimen for intermediate-stage HCC. These points make the current guidelines ambiguous. In this review, we present the Japanese guidelines for the diagnosis and treatment of HCC based on the latest evidence; introduce various efforts mainly in Japanese real-life practice to update these guidelines; and present our perspectives on future guidelines.